Asset

  • No.

    3

  • Asset Title

    NLRC5 as a target to intervene MHC class 1 mediated immune responses

  • Organization

    Dana Farber

  • Product Type

    Gene therapy

  • Therapeutic Area

    Oncology

  • Development Stage

    Hit To Lead or Lead Optimization

  • Technical Summary

    A method to modulate MHC class I gene expression by modulating NLRC5 expression and/or NLRC5 activity in a subject is provided. The method comprises administering to the subject a compound that modulates NLRC5 expression and/or NLRC5 activity in an amount effective to modulate MHC class I gene expression. Also described is a screen for compounds that modulate NLRC5 expression. Candidate compounds are tested for their ability to modulate NLRC5 expression. 

  • Patent

  • Publication

  • Attachment

TOP